HEK293 TSLPR STAT5-Luci Cell Line
Item | Cat# | Price |
Stable Cell Line | SNB-OT-0002 | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine that plays a pivotal role in orchestrating type 2 immune responses at barrier surfaces such as the skin, lung, and gastrointestinal tract. Produced primarily by keratinocytes, airway epithelial cells, and gut epithelium in response to allergens, pathogens, or tissue damage, TSLP signals through a heterodimeric receptor composed of TSLPR and IL-7Rα. Activation of this receptor complex triggers JAK–STAT, PI3K, and NF-κB pathways, leading to strong activation of dendritic cells, which in turn promote Th2 differentiation through OX40L and associated cytokines. TSLP also acts directly on mast cells, basophils, eosinophils, and group 2 innate lymphoid cells, amplifying allergic inflammation. Dysregulated TSLP expression is closely associated with asthma, atopic dermatitis, eosinophilic esophagitis, and other allergic diseases. As a result, TSLP has emerged as an important therapeutic target, exemplified by the anti-TSLP monoclonal antibody tezepelumab.
Screeningbio’s HEK293/TSLP/STAT-3/Luciferase reporter gene cell line stable expressING TSLP and STAT-5 response element and luciferase gene. Upon stimulated, STAT-5 pathway was activated and induce luciferase expression.
Product Specifications
Target Type | TSLPR |
Species | Human |
HGNC Symbol | TSLPR |
Accession Number | NM_022148 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine that plays a central role in initiating type 2 immune responses at barrier surfaces. Produced primarily by keratinocytes, airway epithelial cells, and gastrointestinal mucosa in response to allergens, pathogens, or mechanical injury, TSLP functions as an early “alarmin” that alerts and programs the immune system. TSLP signals through a heterodimeric receptor complex composed of the TSLP receptor (TSLPR) and the interleukin-7 receptor alpha chain (IL-7Rα). Engagement of this receptor activates JAK1/2 and STAT5 pathways, driving the maturation and activation of dendritic cells, which in turn promote Th2 differentiation and downstream production of IL-4, IL-5, and IL-13.
The TSLP–TSLPR axis is critically implicated in the pathophysiology of atopic dermatitis, asthma, allergic rhinitis, and other type 2 inflammatory diseases. Excessive or dysregulated TSLP production amplifies eosinophilic inflammation, IgE class switching, and airway hyperresponsiveness. Beyond classical allergy, TSLP has emerging roles in chronic obstructive pulmonary disease, gastrointestinal inflammation, and tumor microenvironment modulation.
Therapeutically, the pathway has gained significant attention, culminating in the development of tezepelumab, a monoclonal antibody that blocks TSLP and is approved for severe asthma. Targeting TSLP–TSLPR offers a promising upstream strategy to broadly modulate type 2 immunity and treat a range of allergic and inflammatory disorders.